title: Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
abstract: There is controversy over the factors that may influence the outcome of radioiodine therapy for benign thyroid diseases. Antithyroid medication has been claimed to negatively influence the effectiveness of radioiodine therapy in Graves' disease. In a longitudinal study, we assessed the influence of sex, age, antithyroid drugs, target radiation dose, target mass, applied activity, delivered dose, interval between last meal and application, and TSH, FT3 and FT4 levels on the outcome of radioiodine therapy. One hundred and forty-four patients (111 female, 33 male) suffering from Graves' disease (GD) and 563 patients (434 female, 129 male) with toxic nodular goitre (TNG) were entered in the study and followed up until 8 months after therapy. Treatment was defined as successful when the TSH level was found to be normal or elevated. Ninety-eight GD patients and 418 TNG patients were successfully treated. Forward stepwise multiple regression analysis models retained only the target mass in GD and the applied activity in TNG as significantly associated with the outcome of therapy. The predictive value of all variables involved was extremely low in both disease groups. Whereas concomitant antithyroid medication had no influence in GD, it adversely influenced radioiodine therapy of TNG. This effect may be attributed to a radioiodine "steal phenomenon" induced by TSH-stimulated normal thyroid tissue, which causes overestimation of the uptake in toxic nodules.
authors.affiliation: Clinic for Nuclear Medicine, University of Würzburg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Körber
authors.forename: P
authors.initials: P
authors.lastname: Schneider
authors.forename: N
authors.initials: N
authors.lastname: Körber-Hafner
authors.forename: H
authors.initials: H
authors.lastname: Hänscheid
authors.forename: C
authors.initials: C
authors.lastname: Reiners
mesh_terms: D000368:Aged; D013956:Antithyroid Agents / Q000627:therapeutic use*; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D006044:Goiter, Nodular / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy*; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D016896:Treatment Outcome; D014284:Triiodothyronine / Q000097:blood
chemical_list: D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D008713:Methimazole; D002231:Carbimazole; D013972:Thyrotropin; D013974:Thyroxine